Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) EPS (Weighted Average and Diluted) (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed EPS (Weighted Average and Diluted) for 12 consecutive years, with -$0.54 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 23.94% year-over-year to -$0.54, compared with a TTM value of -$2.3 through Sep 2025, up 68.79%, and an annual FY2024 reading of -$2.92, up 86.71% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.54 for Q3 2025 at Alaunos Therapeutics, up from -$0.63 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.03 in Q3 2022 and bottomed at -$11.15 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.65, with a median of -$0.63 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 22200.0% in 2023, then soared 93.63% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.06 in 2021, then plummeted by 4403.34% to -$2.48 in 2022, then crashed by 97.58% to -$4.9 in 2023, then soared by 90.61% to -$0.46 in 2024, then decreased by 17.39% to -$0.54 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TCRT at -$0.54 in Q3 2025, -$0.63 in Q2 2025, and -$0.67 in Q1 2025.